|Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016|
Commenting on the management transition, Mr. Peacock noted:
“Bellerophon has made significant clinical progress of late, most recently having dosed the first patient in its Phase 3 program for the INOpulse® delivery system for patients with Pulmonary Arterial Hypertension (PAH), as well as having dosed the first patient in our Phase 2 trial in patients with pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). In addition, plans are in place to complete further Phase 2 clinical testing for patients suffering from pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
“I am confident that we will have a seamless transition as Fabian and our experienced leadership team continue to execute on these programs. I intend to stay actively involved in the business as Chairman and look forward to us bringing INOpulse therapies to market for these underserved patients.”
Mr. Tenenbaum noted, “I am honored to have been chosen to succeed Jon as CEO. I look forward to continuing to work with our leadership team, lead investigators and other partners to execute on our clinical trials and move the company toward commercialization.”
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) both of which are in Phase 2 development. The Company’s plans call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016. For more information, please visit www.bellerophon.com.
Any statements in this press release about our future expectations, plans and prospects, including statements about clinical development of our product candidates and expectations regarding the sufficiency of our cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our most recent filings with the
Contact At Bellerophon: